Discover and read the best of Twitter Threads about #gicancer
Most recents (2)
Good Morning #GImedTwitter
🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)
🧑🏫Get ready for 3 packed days of presentations at #GI22
And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯
#TumorBoardTuesday
🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)
🧑🏫Get ready for 3 packed days of presentations at #GI22
And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯
#TumorBoardTuesday
#TumorBoardTuesday
1⃣/
Once again HER2🎯💊is everywhere #GI22
👉The DESTINY trials have been👍4⃣T-DXd
✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
1⃣/
Once again HER2🎯💊is everywhere #GI22
👉The DESTINY trials have been👍4⃣T-DXd
✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
#TumorBoardTuesday #GI22
2⃣/
✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
2⃣/
✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
After 19 years, I’ve left Stanford. The accumulated gender discrimination and harassment had taken their toll. I shared my story with @kate_selig and @StanfordDaily because I think it is important and hope it will empower others to speak up.
THREAD 1/
stanforddaily.com/2020/06/10/des…
THREAD 1/
stanforddaily.com/2020/06/10/des…
Stanford was a wonderful place to train and start my career. I had exceptional mentors and colleagues and was given support to start a neuroendocrine tumor program. But then things changed.
2/
2/
As I entered mid-career, assumed leadership roles, and gained some degree of success, I was perceived as a threat by some male colleagues. At that point, I experienced insidious microaggressions and retaliation from male faculty.
3/
3/
